ClinicalTrials.gg
Active, not recruitingNCT04153292ENCIRCLEUpdated Oct 6, 2026

The ENCIRCLE Trial

An interventional study of SAPIEN M3 valve and dock in Mitral Regurgitation and Mitral Valve Insufficiency, sponsored by Edwards Lifesciences. Active, not recruiting at 54 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
786
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Mitral Valve Insufficiency by Edwards Lifesciences — 2 open to participants now, 10 under way, none of them phase 3. Mitral Valve Insufficiency · Edwards Lifesciences.

Enrollment
2nd of 28
786 · median 26
Started
2020
with 3 others
No phase
27 of 33
2 open now
Registered
21st of 33
by date

Among the 33 studies in Mitral Valve Insufficiency by Edwards Lifesciences, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2020, is one of 27 with no phase, and was the 21st registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

2 of the 33 studies in Mitral Valve Insufficiency by Edwards Lifesciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Mitral Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable.

Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

Read the detailed description

This is a prospective single-arm, multicenter study.

03

Conditions studied

  • Mitral Regurgitation
  • Mitral Valve Insufficiency
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. MR ≥ 3+
  3. functional class ≥ II
  4. Per the Heart Team, commercially available surgical or transcatheter treatment options are deemed unsuitable due to clinical, anatomic or technical considerations.
  5. Subject's heart failure management has been optimized based on subject characteristics and applicable guidelines, and stable for at least 30 days prior to enrollment.
  6. The subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the SAPIEN M3 dock or valve
  2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and valve
  3. Presence of any device that will contact or interfere with the SAPIEN M3 System during delivery or after implantation
  4. \<25%
  5. Severe right ventricular dysfunction
  6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months
  7. History of heart transplant
  8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation
  9. Active bacterial endocarditis within 180 days of the procedure
  10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
  11. Myocardial infarction within 30 days of the procedure
  12. untreated coronary artery disease requiring revascularization
  13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of the procedure
  14. Stroke or within 90 days of the procedure
  15. Irreversible, severe pulmonary hypertension
  16. requiring home oxygen therapy or chronic outpatient oral use
  17. Renal insufficiency or receiving renal replacement therapy
  18. Liver disease
  19. Planned surgery within the next 12 months
  20. Inability to tolerate or a medical condition precluding treatment with antithrombotic therapy, including heparin administration during the procedure
  21. Active infection requiring current antibiotic therapy
  22. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments
  23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or hypercoagulable states
  24. Refusal of blood products
  25. Female who is pregnant or lactating
  26. Estimated \<12 months due to non-cardiac conditions
  27. Participating in another drug or device study that has not reached its primary endpoint
  28. Subject considered to be part of a vulnerable population
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
786 participants (actual)

Study arms

  • Experimental
    TMVR - Main Cohort

    Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).

    Device: SAPIEN M3 valve and dock

  • Experimental
    TMVR - Failed TEER Registry

    Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.

    Device: SAPIEN M3 valve and dock

  • Experimental
    TMVR - MAC Registry

    Subjects with mitral annular calcification (MAC) will have TMVR.

    Device: SAPIEN M3 valve and dock

Interventions

  • DeviceSAPIEN M3 valve and dock

    During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

06

What researchers measure

Primary outcomes

  1. Non-hierarchical composite of death and heart failure rehospitalization

    Number of subjects with death and/or heart failure rehospitalization

    Time frame: 1 year

Secondary outcomes

  1. Improvement in NYHA functional class compared to baseline

    New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.

    Time frame: 1 year

  2. Improvement in KCCQ Overall Score compared to baseline

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: 1 year

  3. Improvement in MR compared to baseline

    Number of subjects with improved MR compared to baseline

    Time frame: 1 year

  4. Decrease in LVEDVi compared to baseline

    Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline

    Time frame: 1 year

07

Study locations

54 sites
08

References and documents

Publications

  • Guerrero ME, Daniels DV, Makkar RR, Thourani VH, Asch FM, Pham M, Muhammad KI, Greenbaum AB, Vasquez A, Oldemeyer JB, Dahle TG, Rihal C, Morse MA, Rodriguez E, O'Neill BP, Russo M, Whisenant B, Yadav P, Yu X, Wang DD, Makar M, Baran DA, Mahoney P, Reddy G, Blanke P, Webb J; ENCIRCLE Trial Executive Committee and Study Investigators. Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial. Lancet. 2025 Nov 29;406(10519):2541-2550. doi: 10.1016/S0140-6736(25)02073-2. Epub 2025 Oct 27. PubMed 41167201 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Oct 2027, 82 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 82 months is above that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Feb 2027 → Oct 2027 and completion Feb 2031 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2019
First posted
Nov 6, 2019
StartActual
Nov 12, 2020
Primary completionEst.
Oct 10, 2027was Feb 2027
CompletionEst.
Oct 10, 2031was Feb 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
14 sites removed
Show 14 removed
  • TMC Healthcare · Tucson, United States
  • Saint Joseph Hospital · Orange, United States
  • Delray Medical Center · Delray Beach, United States
  • Rush University Medical Center · Chicago, United States
  • St. Vincent Heart Center of Indiana · Indianapolis, United States
  • Brigham & Women's · Boston, United States
  • Minneapolis Heart · Minneapolis, United States
  • St. Patrick Hospital · Missoula, United States
  • Morristown Medical Center · Morristown, United States
  • Carolinas Medical Center · Charlotte, United States
  • Alleghany General Hospital · Pittsburgh, United States
  • University of Wisconsin · Madison, United States
  • Shaare Zedek Medical Center · Jerusalem, Israel
  • Sheba Medical Center · Ramat Gan, Israel
Oct 6, 2026
Primary completion
Feb 28, 2027→Oct 10, 2027
Oct 6, 2026
Study completion
Feb 28, 2031→Oct 10, 2031
Oct 6, 2026
Enrollment
900 (estimated)→786 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    14 sites removed
    Show 14 removed
    • TMC Healthcare · Tucson, United States
    • Saint Joseph Hospital · Orange, United States
    • Delray Medical Center · Delray Beach, United States
    • Rush University Medical Center · Chicago, United States
    • St. Vincent Heart Center of Indiana · Indianapolis, United States
    • Brigham & Women's · Boston, United States
    • Minneapolis Heart · Minneapolis, United States
    • St. Patrick Hospital · Missoula, United States
    • Morristown Medical Center · Morristown, United States
    • Carolinas Medical Center · Charlotte, United States
    • Alleghany General Hospital · Pittsburgh, United States
    • University of Wisconsin · Madison, United States
    • Shaare Zedek Medical Center · Jerusalem, Israel
    • Sheba Medical Center · Ramat Gan, Israel
    Primary completion Feb 28, 2027→Oct 10, 2027
    Study completion Feb 28, 2031→Oct 10, 2031
    Enrollment 900 (estimated)→786 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04153292
Responsible party
Sponsor
First posted
Nov 6, 2019
Start date
Nov 12, 2020
Primary completion
Oct 10, 2027 (estimated)
Completion
Oct 10, 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

John Webb, MD
principal investigator · St. Paul's Hospital
Mayra Guerrero, MD
principal investigator · Mayo Clinic
David Daniels, MD
principal investigator · California Pacific Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion